Previous 10 | Next 10 |
2023-06-30 14:49:03 ET Shares of the autoimmune specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) rose by as much as 13.2% in early morning trading Friday. The biotech's shares cooled off after their hot start and are up by 8.6% on heavy volume as of 1:41 p.m. ET Friday. The sto...
2023-06-30 14:47:04 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) could see prices in the high $20s to low $30s per share in a takeout at premium multiples, according to RBC, after the company announced Thursday it was exploring alternatives. Aurinia ( AUPH ) rose 9.1%. ...
In Addition, Board has Accepted Recent Director Resignations and has Initiated a Search for New Directors Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has initiated an exploration of stra...
LUPKYNIS® achieved significantly earlier reductions in UPCR and significantly higher renal response rates in lupus nephritis patients with high proteinuria, compared to patients treated with mycophenolate mofetil and low-dose steroids alone, in a pooled, post-hoc analysis. 1 LUPKYNIS...
2023-06-16 15:57:44 ET Summary In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range was increased to between $135 to $155 million of ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV (NCT02141672) and Phase 3 AURORA 1 (NCT03021499) studies, which found that LUPKYNIS® with mycophenolate mofetil (MMF) and low-dose steroids r...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission (SEC). Under U.S. federal securities laws, equity awards issued as employee compensation must be re...
2023-05-22 04:15:56 ET Summary Two of Aurinia's largest shareholders wrote tough letters against the AUPH board, leading to two resignations. One of these shareholders also wanted AUPH to sell out. While a sale has been put on hold for now, any further poor performance will st...
2023-05-17 17:21:57 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) rose 5% in regular trading as two board members, including the chairman, resigned from the board after receiving less than majority support in a shareholder vote on Wednesday. Chairman George Milne and board m...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced voting results for its annual general meeting (the “Meeting”) of shareholders held on May 17, 2023. Shareholders re-elected six of eight incumbent directors to th...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...
2024-06-27 04:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four...